Condition: Locally Advanced Unresectable Uveal Melanoma · Sponsor: Thomas Jefferson University
This is a prospective, single arm, phase II clinical trial of neoadjuvant Tebentafusp (KIMMTRAK®) in patients with locally advanced primary uveal melanoma. Patients must be HLA-A\*02:01 with large, surgically unresectable (other than complete enucleation of the eye) primary uveal melanoma. The efficacy of this treatment will be assessed with the Simon's two stage design. The choice of design is guided by a desire to stop the trial early if the actual regression rate of primary uveal melanoma is 1% or lower.
This description comes directly from the study's public registry record.
Rino Seedor, MD · 215-955-8874 · Rino.Seedor@Jefferson.edu
Rino Seedor, MD
Always discuss trial participation with your own doctor first.
| Sidney Kimmel Cancer Center at Thomas Jefferson University | Philadelphia, Pennsylvania, United States | Recruiting |
| Wills Eye Hospital | Philadelphia, Pennsylvania, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06414590